1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AnGes, Inc.

AnGes, Inc.

AMGXF
AnGes, Inc.US flagOther OTC
0.36
USD
- -
- -
142.50MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.35
23.86
7.74
8.11
4.79
7.02
3.12
0.34
0.44
0.43
0.81
2.74
2.46
2.25
Basic EPS, GAAP
-46.91
-62.12
-74.53
-75.29
-49.38
-34.46
-35.81
-35.33
-92.86
-94.29
-39.29
-119.53
-14.44
-30.61
Free Cash Flow per Basic Share
-48.96
-71.37
-83.87
-79.67
-39.36
-29.59
-20.88
-25.53
-77.82
-71.99
-46.67
-28.43
-16.25
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-216.47
-146.32
-168.29
-184.36
25.89
31.22
27.28
83.66
142.08
51.24
88.05
-39.34
-32.16
70.68
Tangible Book Value per Share
115.59
201.37
75.01
60.12
47.51
88.94
115.11
83.64
108.36
45.95
23.02
9.12
8.65
12.7
Basic Weighted Avg Shares
30
38
56
63
76
87
105
119
147
156
189
235
355
200
Sales/Revenue/Turnover
491
910
430
514
365
610
327
40
64
67
153
644
874
449
Operating Margin (%)
-277.45
-249.9
-969.88
-926.24
-900.56
-502.46
-1,000.74
-13,999.18
-24,369.16
-24,331.65
-7,822.66
-1,415.31
-588.64
-2,475.71
Depreciation Expense
60
46
49
67
29
8
7
8
2,426
2,902
3,109
3,372
54
- -
Net Income, GAAP
-1,410
-2,369
-4,143
-4,777
-3,765
-2,997
-3,751
-4,210
-13,676
-14,715
-7,438
-28,129
-5,123
-6,108
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
42.64
Profit Margin (%)
-286.92
-260.37
-963.22
-928.85
-1,030.91
-491.21
-1,147.89
-10,524.3
-21,319.14
-21,942.7
-4,861.66
-4,370.31
-586.11
-1,359.35
Working Capital
2,959
7,171
3,761
2,989
3,116
7,251
10,549
8,577
14,693
5,573
3,428
1,229
2,143
1,662
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
995
215
109
- -
174
Total Equity
3,544
7,734
4,221
3,869
3,622
7,734
12,055
32,680
38,635
30,425
26,103
2,157
3,076
25,477
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-60.1
Return on Common Equity (%)
- -
- -
- -
- -
- -
-127.84
-134.63
-65.64
-88.54
-101.76
-60.31
- -
- -
-37.15

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
148
155
162
LT Borrowings
- -
- -
- -
LT Finance Leases
215
197
174
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
198
201
237
Market Capitalization
- -
13,914
10,414

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
5,921
4,393
3,591
Cash, Cash Equivalents & STI
4,160
2,116
1,821
Accounts Receivable, Net
27
98
200
Inventories
1,566
1,939
1,303
Total Current Liabilities
2,493
2,690
1,929
Payables & Accruals
- -
- -
- -
ST Debt
148
155
162
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.94%
-13.27%
42.64%
Free Cash Flow
19.29%
43.05%
-13.84%
Net Income, GAAP
39.05%
75.89%
-81.79%
Sales/Revenue/Turnover
47.3%
109.92%
35.81%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
114
234
- -
- -
644
2025
- -
- -
- -
- -
874
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-9.14
- -
- -
- -
-119.53
2025
- -
- -
- -
- -
-14.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Ei Yamada
Full Time Employees
55
Sector
Healthcare
Industry
Biotechnology
Address
Saito Bio-Incubator Ibaraki Japan 567-0085
IPO Date
Jul 3, 2017
Website
anges.co.jp
Similar Companies
PureTech Health plc (PTCHF)
Starpharma Holdings Limited (SPL.AX)
BioMarin Pharmaceutical Inc. (BM8.F)
Larimar Therapeutics, Inc. (LRMR)
Ryvu Therapeutics S.A. (RVU.WA)
Ginkgo Bioworks Holdings, Inc. WT (DNA-WT)
Business
AnGes, Inc. is a Japanese biopharmaceutical company specializing in the research, development, and marketing of gene-based medicines and gene therapy products. Its core products include hepatocyte growth factor (HGF) gene therapy for ischemic diseases such as chronic arterial occlusive disease; NF-κB decoy oligonucleotides for chronic discogenic lumbar back pain; DNA vaccines; and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vectors. The company also develops genome editing technology platforms and products through its consolidated subsidiary EmendoBio Inc., expanding its capabilities in advanced gene therapy. AnGes operates primarily in Japan, the United States, and other international markets, supported by subsidiaries including AnGes USA, Inc. and EmendoBio Inc., both headquartered in Jersey City, New Jersey. Founded in December 1999 and headquartered in Ibaraki, Japan, AnGes focuses its business segments on nucleic acid medicine and genomic drug discovery targeting intractable, rare diseases, and diseases lacking effective treatments. Recent major developments include the FDA granting Breakthrough Therapy designation in 2024 for its flagship HGF gene therapy product. The company is actively developing a Tie2 tyrosine kinase receptor agonist (AV-001) for viral and bacterial-associated pneumonia and continuing advancement of NF-κB decoy oligonucleotide treatments. Strategic expansions include the acquisition of EmendoBio Inc. in December 2020 to strengthen genome editing technology and the establishment of new R&D bases, including in the U.S. Additionally, AnGes has engaged in strategic alliances, such as co-development partnerships with Vasomune Therapeutics for COVID-19/ARDS therapeutics and MyBiotics Pharma for microbiome-related treatments. These initiatives underscore AnGes' commitment to advancing innovative gene-based medicines for global markets.